Deimmunized Pseudomonas Exotoxin A

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes novel versions of the bacterial toxin Pseudomonas exotoxin A (PE) that have been genetically engineered to reduce their immunogenicity (the likelihood of triggering immune responses) while maintaining or improving their cell-killing (cytotoxic) and enzymatic activity. These 'deimmunized' PE variants are especially suited for use as part of targeted therapies, often as immunotoxins where the toxin is linked to molecules (such as antibodies or allergens) that guide them to specific cells (like cancer cells or allergen-reactive B-cells). The invention also details nucleic acids, vectors, and host cell systems for producing these proteins, as well as methods of use for treating various cancers, inflammatory diseases, and allergies, including allergic asthma.

Use CasesContent extracted from patent full text and abstract with AI.

• Targeted cancer therapy using immunotoxins to selectively destroy cancer cells in hematological (blood) and solid tumors.
• Development of novel treatments for chronic inflammatory diseases such as rheumatoid arthritis and multiple sclerosis.
• Specific depletion of allergen-reactive B-cells for curative therapy of severe allergies and allergic asthma.
• Creation of diagnostic tools or research reagents for identifying or studying B-cell populations relevant in disease.
• Use in drug development platforms to create safer and more effective protein-based therapeutics with reduced side effects due to lower immunogenicity.

BenefitsContent extracted from patent full text and abstract with AI.

• Reduced immunogenicity means fewer adverse immune responses, allowing for higher or more frequent dosing and improved patient outcomes.
• Maintained or enhanced cytotoxic activity despite modifications, ensuring therapeutic effectiveness.
• Enables precise targeting of diseased cells (such as cancer or allergy-producing B-cells) with less collateral damage to healthy tissues.
• Broad application potential: can be used for cancer, inflammatory diseases, and allergies, including forms resistant to current therapies.
• Compatibility with recombinant production methods allows scalable, reliable, and more cost-effective manufacturing of these therapeutic agents.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The technology provided herein relates to novel Pseudomonas exotoxin A enzymes (PEs); to nucleic acid molecules encoding said PEs, vectors, host cells containing the nucleic acids and methods for preparation and producing such PEs; compositions and methods for using said PEs for the treatment of diseases, in particular cancers especially including hematological and solid malignancies, chronic inflammatory diseases and allergies including allergic asthma.